Sinovac Biotech (SVA) Management Buyout Offer Undervalues Company by 75% - Heng Ren

August 31, 2016 7:20 AM EDT
Get Alerts SVA Hot Sheet
Price: $6.10 -0.16%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade SVA Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

The management bid for Sinovac Biotech Limited (NASDAQ: SVA) needs to be raised by 75%, Peter Halesworth, Managing Partner of Heng Ren Investments LP and a Sinovac shareholder, argued in a letter to the board.

Halesworth and Thomas D. Grant, CFA, co-author of the analysis, showed that Sinovac’s intrinsic value is $10.84, versus The Insider's buyout offer of just $6.18 per share.

In the analysis, Halesworth and Grant said annual sales of EV71, Sinovac’s breakthrough vaccine to inoculate children in China from Hand, Foot, and Mouth Disease (HFMD), could eventually reach $400 million.

"The management buyout offer is an epic failure of corporate governance by Sinovac’s Insiders, and a red flag for the future,” stated Peter Halesworth, Managing Partner of Heng Ren Investments LP and a Sinovac shareholder. “If this poor treatment of shareholders is rewarded, it will surely be repeated.”

Link to Press Release



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hedge Funds, Mergers and Acquisitions, Rumors

Add Your Comment